Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Research & Development (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Research & Development readings, the most recent being $1.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 61.56% year-over-year to $1.1 million, compared with a TTM value of $7.9 million through Dec 2025, down 29.87%, and an annual FY2025 reading of $7.9 million, down 29.87% over the prior year.
  • Research & Development hit $1.1 million in Q4 2025 for Lisata Therapeutics, down from $2.0 million in the prior quarter.
  • The five-year high for Research & Development was $3.4 million in Q3 2023, with the low at $1.1 million in Q4 2025.
  • Median Research & Development over the past 3 years was $2.8 million (2024), compared with a mean of $2.7 million.
  • The sharpest move saw Research & Development increased 1.95% in 2024, then tumbled 61.56% in 2025.
  • Year by year, Research & Development stood at $3.0 million in 2023, then decreased by 2.09% to $2.9 million in 2024, then plummeted by 61.56% to $1.1 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $1.1 million, $2.0 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.